CervoMed (CRVO) Non-Current Assets (2010 - 2024)
CervoMed (CRVO) posted Non-Current Assets of $73937.0 for Q3 2024, down 98.74% sequentially from $5.9 million in Q2 2024, and down 61.97% YoY from $194443.0 in Q4 2023.
CervoMed (CRVO) Non-Current Assets (2010 - 2024) Analysis & Trends
CervoMed has reported Non-Current Assets for 14 years, with the latest figure at $73937.0 in Q3 2024.
- Quarterly Non-Current Assets fell 61.97% year-over-year to $73937.0 in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $73937.0 (down 98.79% YoY) and the FY2023 annual result came in at $7770.0, changed N/A from the prior year.
- Non-Current Assets declined to $73937.0 in Q3 2024 per CRVO's latest filing, from $5.9 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $9.3 million in Q1 2020 and troughed at -$14.5 million in Q1 2023.
- A 4-year average of $3.3 million and a median of $3.0 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2024: Non-Current Assets slumped 99.83% in 2021, then jumped 100.22% in 2024.
- Over 4 years, Non-Current Assets stood at $9.0 million in 2020, then plunged by 99.83% to $15578.0 in 2021, then slumped by 50.12% to $7770.0 in 2023, then jumped by 851.57% to $73937.0 in 2024.
- According to Business Quant data, Non-Current Assets over the past three periods registered $73937.0, $5.9 million, and $31926.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.19 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.58 Bn | 77.59 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.34 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 56.52 Bn | 51.38 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.67 Bn | 27.36 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.27 Bn | 26.11 Bn | 358.27 Mn | 468.65 Mn |
| 8 | BioNTech SE | 27.14 Bn | 8.75 Bn | 668.28 Mn | 6.80 Bn |
| 9 | Royalty Pharma | 27.12 Bn | 26.28 Bn | - | 18.06 Bn |
| 10 | CervoMed | 26.50 Mn | 26.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 73,937.00 |
| Jun 30, 2024 | 5.86 Mn |
| Mar 31, 2024 | 31,926.00 |
| Dec 31, 2023 | 7,770.00 |
| Sep 30, 2023 | 194,443.00 |
| Mar 31, 2023 | -14.46 Mn |
| Dec 31, 2021 | 15,578.00 |
| Sep 30, 2021 | 165,361.00 |
| Jun 30, 2021 | 8.85 Mn |
| Mar 31, 2021 | 8.90 Mn |
| Dec 31, 2020 | 8.95 Mn |
| Sep 30, 2020 | 9.24 Mn |
| Jun 30, 2020 | 9.28 Mn |
| Mar 31, 2020 | 9.34 Mn |
| Dec 31, 2019 | 9.46 Mn |
| Sep 30, 2019 | 9.48 Mn |
| Jun 30, 2019 | 9.52 Mn |
| Mar 31, 2019 | 9.60 Mn |
| Dec 31, 2018 | 9.29 Mn |
| Sep 30, 2018 | 12.02 Mn |